1. Home
  2. NAOV vs ENTO Comparison

NAOV vs ENTO Comparison

Compare NAOV & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAOV
  • ENTO
  • Stock Information
  • Founded
  • NAOV 2003
  • ENTO 2014
  • Country
  • NAOV United States
  • ENTO United States
  • Employees
  • NAOV N/A
  • ENTO N/A
  • Industry
  • NAOV Industrial Specialties
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAOV Health Care
  • ENTO Health Care
  • Exchange
  • NAOV Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • NAOV 2.4M
  • ENTO 1.9M
  • IPO Year
  • NAOV N/A
  • ENTO 2016
  • Fundamental
  • Price
  • NAOV $0.90
  • ENTO $0.52
  • Analyst Decision
  • NAOV
  • ENTO
  • Analyst Count
  • NAOV 0
  • ENTO 0
  • Target Price
  • NAOV N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • NAOV 4.9M
  • ENTO 3.2M
  • Earning Date
  • NAOV 05-20-2025
  • ENTO 06-17-2025
  • Dividend Yield
  • NAOV N/A
  • ENTO N/A
  • EPS Growth
  • NAOV N/A
  • ENTO N/A
  • EPS
  • NAOV N/A
  • ENTO N/A
  • Revenue
  • NAOV $2,662,000.00
  • ENTO N/A
  • Revenue This Year
  • NAOV N/A
  • ENTO N/A
  • Revenue Next Year
  • NAOV N/A
  • ENTO N/A
  • P/E Ratio
  • NAOV N/A
  • ENTO N/A
  • Revenue Growth
  • NAOV N/A
  • ENTO N/A
  • 52 Week Low
  • NAOV $0.67
  • ENTO $0.19
  • 52 Week High
  • NAOV $16.25
  • ENTO $2.64
  • Technical
  • Relative Strength Index (RSI)
  • NAOV 30.09
  • ENTO 69.29
  • Support Level
  • NAOV $0.67
  • ENTO $0.35
  • Resistance Level
  • NAOV $1.08
  • ENTO $0.50
  • Average True Range (ATR)
  • NAOV 0.19
  • ENTO 0.08
  • MACD
  • NAOV 0.05
  • ENTO 0.01
  • Stochastic Oscillator
  • NAOV 25.80
  • ENTO 51.85

About NAOV NanoVibronix Inc.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: